Drug delivery device manufacturer Nemera has announced a new strategic partnership with pharmaceutical company Therakind to advance the DriDose intranasal platform.
The new collaboration will bring together Nemera's knowledge in combination product device development and industrialisation, with Therakind's experience in developing and delivering innovative medicines to patients.
The DriDose platform (a dry powder intranasal device portfolio developed by Therakind) complements Nemera's existing range of nasal delivery solutions, which currently supports liquid formulations.
The partnership enables Nemera to expand its innovative nasal portfolio by adding a complete dry powder delivery platform, further enhancing its comprehensive offering for pharmaceutical and biotechnology partners.
Therakind, a UK-based pharmaceutical company known for advancing products from development to regulatory approval, is consolidating its core business to focus on developing drug-device combination products.
The company will continue to utilise the DriDose platform to improve patient outcomes through both internal projects and collaborations with external partners.
Dr Susan Conroy, CEO of Therakind, said: "We are delighted to partner with Nemera, known for its expertise in drug delivery solutions and novel device industrialisation."
As a market leader in devices with a global presence, Nemera is an ideal partner for the DriDose portfolio industrialisation and expansion.
Dimitri Grasswill, Vice President of Nemera's Ear, Nose and Throat business, added: "We are thrilled to partner with Therakind and benefit from their strong track record in pharmaceutical development and regulatory approvals."
The innovative DriDose technology will open Nemera to new therapeutic areas in nasal drug delivery and will significantly improve patients' lives — it perfectly complements our product portfolio, especially by targeting unmet needs in systemic and non-systemic treatments.